CORE
CO
nnecting
RE
positories
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Research partnership
About
About
About us
Our mission
Team
Blog
FAQs
Contact us
Community governance
Governance
Advisory Board
Board of supporters
Research network
Innovations
Our research
Labs
research
Fk506 “rescue” for resistant rejection of renal allografts under primary cyclosporine immunosuppression
Authors
G Carrieri
AJ Demetris
+11 more
JJ Fung
TR Hakala
ML Jordan
J Mc Cauley
P Rhandhawa
VP Scantlebury
R Shapiro
RL Simmons
TE Starzl
A Tzakis
CA Vivas
Publication date
1 January 1994
Publisher
'Ovid Technologies (Wolters Kluwer Health)'
Doi
View
on
PubMed
Abstract
Seventy-seven patients with ongoing acute rejection on initial CsA therapy were converted to FK506 to attempt graft salvage. Fifty-nine patients had undergone primary transplantation and 18 had been retransplanted; there were 52 cadaveric and 25 living-donor transplants. The indications for conversion to FK506 were ongoing, biopsy-confirmed rejection in all patients, including vascular rejection in 20. The median interval to rescue was 2 months (range 2 weeks to 36 months) after transplantation. Sixty-one of the 77 patients (79%) had already received one or more courses of an antilymphocyte preparation (OKT3: n=33; ALG or ATG: n=1; OKT3+ALG/ATG: n=27). Of the 77 patients, 57 (74%) have been successfully rescued and still have functioning grafts with a mean follow-up of 14 months, with a mean serum creatinine of 2.35±0.97 mg/dl. Eighteen patients were already dialysis-dependent at the time of conversion to FK506; of these, 9 (50%) were successfully salvaged and have a mean serum creatinine of 2.3 mg/dl. Of the 61 patients previously treated with antilymphocyte preparations, 48 (79%) were rescued. In those salvaged, prednisone doses have been lowered from 22.2±7.2 mg/day preconversion to 7.5±5.6 mg/day postconversion, and 12 patients are on FK506 monotherapy. In nondiabetics, mean serum glucose was 101.4±20.5 mg/dl preconversion and 93.2±22 postconversion (P=0.07), uric acid 7.3±2.3 and 7.1±1.5 mg/dl (P=0.53), and triglycerides 199.2±101.6 and 167.2±106.4 mg/dl (P=0.06). Cholesterol levels were significantly lower following FK conversion (207.7±46.5 mg/dl pre. vs. 188.3±39.7 post, P=0.007). FK506 is capable of salvaging renal allografts with ongoing acute rejection on CsA therapy, even when antilymphocyte preparations have been ineffective. © 1994 by Williams and Wilkins
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Name not available
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:d-scholarship.pitt.edu:500...
Last time updated on 15/12/2016
D-Scholarship@Pitt
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:d-scholarship.pitt.edu:500...
Last time updated on 19/07/2013
Name not available
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:d-scholarship.pitt.edu:500...
Last time updated on 23/11/2016
Crossref
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 05/06/2019